Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors

Ignacio Varela; Pablo Menendez; Alejandra Sanjuan-Pla

doi:10.18632/oncotarget.20279

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meeting Reports:

Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors

Ignacio Varela, Pablo Menendez and Alejandra Sanjuan-Pla _

PDF | HTML | How to cite

Oncotarget. 2017; 8:66742-66746. https://doi.org/10.18632/oncotarget.20279

Metrics: PDF 1198 views | HTML 2036 views | ?

Abstract

Ignacio Varela1, Pablo Menendez2,3,4 and Alejandra Sanjuan-Pla5

1 Instituto de Biomedicina y Biotecnología de Cantabria, Universidad de Cantabria-CSIC, Santander, Spain

2 Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Barcelona, Spain

3 Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain

4 Red de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Barcelona, Spain

5 Hematology Research Group, IIS La Fe, Valencia, Spain

Correspondence to:

Alejandra Sanjuan-Pla, email:

Keywords: cancer genomics, intratumoral heterogeneity, tumor evolution, oncology practice, bioinformatics

Received: June 16, 2017 Accepted: July 25, 2017 Published: August 16, 2017

Abstract

This meeting held at the University of Barcelona in March 2017, brought together scientists and clinicians worldwide to discuss current and future clinico-biological implications of intratumoral heterogeneity (ITH) and subclonal evolution in cancer diagnosis, patient stratification, and treatment resistance in diagnosis, treatment and follow-up. There was consensus that both longitudinal and tumor multi-region studies in matched samples are needed to better understand the dynamics of ITH. The contribution of the epigenome and microenvironment to ITH and subclone evolution remains understudied. It was recommended to combine computational, pathology and imaging tools to study the role of the microenvironment in subclone selection/evolution.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20279

Publication Alerts

Post-Publication Promotion

Publication Discount

Meeting Reports:

Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors

Abstract